Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28967485

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Nov
First author
Balar AV

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Nov;18(11):1428-1430. doi: 10.1016/S1470-2045(17)30602-2.
    note
    Source null
    related pmid
    28967486
    relationship
    Comment in

Authors and identifiers

  1. name
    Balar AV
    type
    Author
  2. name
    Castellano D
    type
    Author
  3. name
    O'Donnell PH
    type
    Author
  4. name
    Grivas P
    type
    Author
  5. name
    Vuky J
    type
    Author
  6. name
    Powles T
    type
    Author
  7. name
    Plimack ER
    type
    Author
  8. name
    Hahn NM
    type
    Author
  9. name
    de Wit R
    type
    Author
  10. name
    Pang L
    type
    Author
  11. name
    Savage MJ
    type
    Author
  12. name
    Perini RF
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Balar AV
    type
    Author
  2. name
    Castellano D
    type
    Author
  3. name
    O'Donnell PH
    type
    Author
  4. name
    Grivas P
    type
    Author
  5. name
    Vuky J
    type
    Author
  6. name
    Powles T
    type
    Author
  7. name
    Plimack ER
    type
    Author
  8. name
    Hahn NM
    type
    Author
  9. name
    de Wit R
    type
    Author
  10. name
    Pang L
    type
    Author
  11. name
    Savage MJ
    type
    Author
  12. name
    Perini RF
    type
    Author
bibliography ids
  1. nci-bib-d681e2e72bc8f8505c5b1618
book metadata
content sha256
a60129a34cd3c42510f4aa5e441f366d127a5830aab729eba6db469b30db71a2
document type
citation
dois
  1. 10.1016/S1470-2045(17)30616-2
electronic publication date
display
2017 Sep 26
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28967485
immutable id
pubmed:28967485@a60129a34cd3c42510f4aa5e441f366d127a5830aab729eba6db469b30db71a2
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1483-1492
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Nov;18(11):1428-1430. doi: 10.1016/S1470-2045(17)30602-2.
    note
    Source null
    related pmid
    28967486
    relationship
    Comment in
outcomes validated
false
pmid
28967485
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
46739f32ca8034ccbaafa80b8c96af4071e482764f3938c7ba2de80e7a34d3b3
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Nov
precision
month
year
2017
publication types
  1. Clinical Trial, Phase II
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28967485/
title
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Preserved source evidence · Not medical advice